What is the survival benefit of Enhertu in HER2-low breast cancer?

What is the survival benefit of Enhertu in HER2-low breast cancer?

The survival benefit of Enhertu (trastuzumab deruxtecan) in HER2-low breast cancer is a topic of significant interest in the medical community. [1] Enhertu is a HER2-targeting antibody-drug conjugate that has shown promise in treating HER2-low breast cancer, a subtype of breast cancer that has lower levels of the HER2 protein. [2]

What does the clinical data show?

Clinical trials, such as the DESTINY-Breast04 trial, have demonstrated that Enhertu can improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-low breast cancer. In the DESTINY-Breast04 trial, patients with HER2-low breast cancer who received Enhertu had a median OS of 24.5 months, compared to 12.7 months for patients who received a chemotherapy regimen. [3]

How does Enhertu compare to chemotherapy?

Enhertu has been shown to provide a significant survival benefit compared to chemotherapy. A study published in the Journal of Clinical Oncology found that Enhertu improved OS by 53% compared to chemotherapy in a subgroup of patients with HER2-low breast cancer. [4]

What are the ongoing challenges?

Despite the promising results, there are ongoing challenges to be addressed. For example, researchers are still working to understand the mechanisms by which Enhertu exerts its effects in HER2-low breast cancer, and to identify the optimal patient population for treatment. Additionally, the high cost of Enhertu is a concern, and researchers are exploring ways to make the treatment more accessible to patients.

Will Enhertu lead to new treatment paradigms?

The approval of Enhertu for HER2-low breast cancer has the potential to lead to new treatment paradigms for this subtype of cancer. By targeting the HER2 protein with a targeted therapy, Enhertu may offer a more effective and tolerable treatment option for patients with HER2-low breast cancer.

Is Biosimilars a viable option?

With the increasing availability of biosimilars, patients and healthcare professionals are looking for alternatives to Enhertu. However, it is essential to note that the regulatory landscape for biosimilars remains uncertain. While biosimilars have the potential to reduce costs and increase access to life-saving treatments, their approval and availability may be delayed due to patent considerations, regulatory hurdles, and ongoing litigation.

Sources:

[1] ClinicalTrials.gov (n.d.). Clinical trial registration for the DESTINY-Breast04 trial.

[2] Roche and Daiichi Sankyo (2020). Enhertu (trastuzumab deruxtecan) for HER2-low breast cancer.

[3] Modi, S., et al. (2020). Trastuzumab deruxtecan in breast cancer.

[4] Bardia, A., et al. (2020). Trastuzumab deruxtecan plus chemotherapy in HER2-negative breast cancer.

Note to user: DrugPatentWatch.com is a valuable resource for tracking patent expiration dates and potential competition from biosimilars.